CRISPR Therapeutics (CRSP) News Today

CRISPR Therapeutics AG (NASDAQ: CRSP) shares have moved higher as investors weigh supportive analyst ratings and modestly improved earnings forecasts against continued projected losses.

• Positive Sentiment: HC Wainwright remains bullish: The firm maintained a “Buy” rating and an $80 price target, while modestly narrowing its projected losses for fiscal 2026, fiscal 2027 and fourth-quarter 2027. The revisions suggest slightly better expected profitability, although CRISPR is still forecast to remain unprofitable. HC Wainwright CRISPR Therapeutics estimates
• Positive Sentiment: Other bullish coverage supports sentiment: Piper Sandler reaffirmed its “Buy” rating on CRISPR Therapeutics, while Brookline Capital Markets raised its fiscal 2027 EPS forecast to a loss of $4.51 from a loss of $5.05. Piper Sandler reaffirms Buy rating
• Neutral Sentiment: Wells Fargo issued a Hold rating: The rating indicates a more cautious view and may limit the impact of the bullish recommendations, particularly with CRSP still reporting substantial losses. Wells Fargo Hold rating
• Negative Sentiment: Brookline lowered its fiscal 2026 outlook: The firm increased its projected fiscal 2026 loss to $5.63 per share from $5.36 and reduced its fourth-quarter 2026 forecast to a $1.87-per-share loss from $1.69. These revisions highlight near-term earnings pressure.

Overall, the positive analyst ratings, higher long-term earnings estimates and $80 HC Wainwright target appear to be supporting CRSP. However, the company’s ongoing losses and Brookline’s weaker 2026 forecast remain risks for investors.